Form 4: Coeptis Therapeutics Holdings CEO Receives Stock Options Grant

CEO David Mehalick received a grant of 28,875 non-qualified stock options on March 4, 2025, under the company's 2022 equity incentive plan.

Summary

• On March 4, 2025, David Mehalick, CEO and President of Coeptis Therapeutics Holdings, Inc., received a grant of 28,875 non-qualified stock options.
• These options were granted under the company's 2022 equity incentive plan.
• The exercise price of the options is equal to the fair market value (FMV) of the company's stock price on the Nasdaq Capital Market on the grant date.
• The options will vest over four years in equal quarterly installments, with the final vesting date on December 31, 2028.
• The options expire ten years from the grant date.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive. The grant of stock options is a standard practice and suggests confidence in the company's future performance, as it incentivizes the CEO to increase shareholder value.

Positives

• The grant of stock options aligns the CEO's interests with those of the shareholders, incentivizing him to increase the company's value.
• The vesting schedule encourages long-term commitment from the CEO.

Industry Context

Stock option grants are a common practice in the biotechnology industry to incentivize executives and align their interests with those of shareholders. The specific terms of the grant, such as the vesting schedule and exercise price, are typical for executive compensation packages.

Comparison to Industry Standards

• Stock option grants are a standard component of executive compensation packages in the biotech industry.
• Vesting schedules of four years with quarterly installments are common.
• Exercise prices typically align with the fair market value at the time of the grant.
• Comparing the size of the grant to similar companies would require further analysis of Coeptis's compensation strategy and market capitalization.

Stakeholder Impact

• Shareholders: The grant aligns the CEO's interests with increasing shareholder value.
• Employees: The grant may boost employee morale by demonstrating confidence in the company's leadership and future prospects.

Key Dates